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Regulation of Bidirectional Melanosome Transport
by Organelle Bound MAP Kinase
the upstream ERK kinase known as MEK (for a review
of MAPK pathways, see [7]).
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University of Illinois at Urbana-Champaign melanosome aggregation by melatonin (Figure 1A),
whereas the inactive analog U0124 had no effect. InUrbana, Illinois 61801
addition, treatment with U0126 did not prevent melano-
cyte-stimulating hormone (MSH)-dependent melanosome
dispersion (Figure 1B). The inhibition of melanosome
aggregation in the presence of U0126 was not due to
Summary
changes in the cytoskeleton because microtubules and
actin filaments in cells treated with U0126 show no obvi-
Regulation of intracellular transport plays a role in a
ous morphological changes when compared to control
numberof processes, includingmitosis, determination
cells (Figures S1 and S2 in the Supplemental Data avail-
of cell polarity, and neuronal growth. In Xenopusmela-
able with this article online).
nophores, transport of melanosomes toward the cell
Melanosomes in cells treated with melatonin and
center is triggered bymelatonin, whereas their disper-
U0126 undergo very few long-range movements, sug-
sion throughout the cytoplasm is triggered bymelano-
gesting that the microtubule-dependent component of
cyte-stimulating hormone (MSH), with both of these pro-
transport has been inhibited (Movies S1 and S2). Mela-
cesses mediated by cAMP-dependent protein kinase
nophores were pretreated with 5 M latrunculin B to
A (PKA) activity [1, 2]. Recently, the ERK (extracellular
depolymerize actin filaments and then stimulated with
signal-regulated kinase) pathway has been implicated
melatonin or MSH in conjunction with U0126 or DMSO
in regulating organelle transport and signaling down-
to determine exactly how ERK signaling affects melano-
stream of melatonin receptor [3, 4]. Here, we directly
some transport along microtubules. Analysis of melano-
demonstrate that melanosome transport is regulated
some movements under these conditions demonstrates
by ERK signaling. Inhibition of ERK signaling by the
that inhibition of ERK signaling greatly inhibits the num-
MEK (MAPK/ERK kinase) inhibitor U0126 blocks bidi-
ber of melanosome runs along microtubules both to-
rectional melanosome transport along microtubules,
ward (retrograde) and away from (anterograde) the cell
and stimulationof ERKby constitutively activeMEK1/2
center during aggregation and dispersion. Analysis of
stimulates transport. These effects are specific be-
those few melanosomes that do move in the presence
cause perturbation of ERK signaling has no effect on
of U0126 revealed no statistically significant effect on
the movement of lysosomes, organelles related to
either run velocity or run length (Table 1; Figure S3).
melanosomes [5]. Biochemical analysis demonstrates
Despite the dramatic inhibition of transport during MSH
that MEK and ERK are present on melanosomes and
treatment, melanosome dispersion still occurs (Figure
transiently activated by melatonin. Furthermore, this
1B). This is likely due to the fact that myosin-V-mediated
activation correlates with an increase in melanosome
transport along actin filaments is sufficient to disperse
transport. Finally, direct inhibition of PKA transiently
melanosomes in the absence of microtubules [8, 9]. In
activates ERK, demonstrating that ERK acts down-
support of this conclusion, U0126 treatment has no ef-
stream of PKA.We propose that signaling of organelle
fect on the ability of myosin V to disperse melanosomes
bound ERK is a key pathway that regulates bidirec-
in cells treated with nocodazole (Figure 1C).
tional, microtubule-based melanosome transport.
To further explore a role for ERK in melanosome trans-
port, we created GFP fusions of constitutively active
forms of rat MEK1 (GFP-CA-MEK1) and MEK2 (GFP-Results
CA-MEK2) and expressed these proteins in melano-
phores. We first confirmed that these fusion proteinsThe ERK Pathway Regulates Bidirectional
are able to phosphorylate Xenopus ERK (Figure S4) andMelanosome Transport
then examined the effect of their expression on melano-Melanosome transport is regulated by changes in PKA
some transport along microtubules. Transfection withactivity [1, 2], and there is extensive evidence pointing
either GFP-CA-MEK1 or GFP-CA-MEK2 increases theto crosstalk between cAMP-dependent signaling and
number of moving melanosomes in both directions inthe ERK pathway [6]. It has also been shown that signal-
MSH with no significant change in run velocity or runing through melatonin receptors targets the ERK path-
length. (Table 1; Figure S3). In melatonin-treated cells,way [3, 4]. In light of this evidence, it is important to
there is a substantial increase in the number of antero-understand how perturbation of ERK signaling affects
grade runs, whereas the increase in retrograde runsmelanosome transport in vivo. In order to do so, melano-
in cells expressing GFP-CA-MEK1/2 is not statisticallyphores were treated with U0126, a potent inhibitor of
significant (p  0.18 and 0.06, respectively). It is likely
that melatonin treatment fully activates retrograde mela-
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[10]), possibly masking CA-MEK-dependent transportberg School of Medicine, Northwestern University, 303 East Chicago
Avenue, Ward 11-080, Chicago, Illinois 60611-3008. stimulation. When combined with analysis of melano-
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Figure 1. Inhibition of ERK Signaling Prevents Melanosome Aggregation but Not Dispersion
(A) Melanophores treated with melatonin (MEL) in the presence of 50 M U0126 are unable to aggregate melanosomes in comparison to
controls (DMSO or U0124).
(B) Melanosome dispersion by MSH is not affected by U0126.
(C) Myosin-V-based melanosome dispersion along actin filaments in cells treated with nocodazole (noc.) in the presence of MSH is unaffected
by treatment with U0126. In this experiment, melanophores were treated with melatonin and then melatonin, nocodazole, and U0126, then
switched into MSH plus nocodazole and U0126. In each experiment, aggregated, partially dispersed, and dispersed cells are shown as white,
light gray, and dark gray bars, respectively. n  200 for each condition.
some transport in cells treated with U0126, the results transport. Furthermore, this result, together with data
obtained from cytoskeletal staining experiments (Figureof melanosome analysis in cells expressing CA-MEK1/2
clearly demonstrate that ERK signaling is a key modula- S1 and S2), argues against the ERK pathway having
an effect on transport via global rearrangements of thetor of bidirectional melanosome transport.
cytoskeleton.
ERK Signaling Does Not Affect
Lysosome Movements Transient Activation of MEK, ERK, and Melanosome
Transport during AggregationIn order to determine whether ERK signaling specifically
regulates melanosome transport, we chose to study the In light of the dramatic melanosome-transport changes
obtained by manipulating the ERK pathway and of theeffect of U0126 on the transport of lysosomes, organ-
elles related to melanosomes but transported by differ- U0126-dependent block of aggregation, it is important
to understand the kinetics of ERK signaling and melano-ent motor proteins and subject to different regulatory
mechanisms [5, 11]. Analysis of lysosome transport (Ta- some movements during melatonin treatment. We ob-
served dramatic activation of MEK and ERK in melano-ble 2; Figure S5) demonstrates that inhibition of ERK
signaling by U0126 has no effect on lysosome transport phore extracts within the first 5 min of melatonin
treatment; the activation subsides as treatment timein either melatonin- or MSH-treated cells, indicating that
ERK regulatory effects are specific for melanosome increases (Figure 2A, top panels). These observations
Table 1. Melanosome Transport and ERK Signaling
Number of Number of Average Average
Anterograde Retrograde Velocity Run Length
Condition Drug Runs Runsa (m/s) (m) n
Melatonin DMSO 4.0  0.3 8.2  0.7 0.32  0.1 1.02  0.4 892
Melatonin U0126 0.3  0.5b 0.3  0.5b 0.25  0.1 0.59  0.3 1968
MSH DMSO 4.8  2.8 2.7  1.4 0.28  0.1 0.81  0.6 957
MSH U0126 0.6  0.8b 0.4  0.5b 0.28  0.1 0.68  0.4 1435
Transfection
Melatonin GFP 4.3  1.5 6.3  3.7 0.31  0.1 0.99  1.0 1068
Melatonin GFP-MEK1 6.0  0.9b 7.6  2.5 0.32  0.1 1.11  1.2 1194
Melatonin GFP-MEK2 5.7  1.3b 8.1  3.1 0.33  0.1 1.13  1.1 1194
MSH GFP 3.7  1.5 2.6  1.1 0.27  0.1 0.78  0.6 1872
MSH GFP-MEK1 5.6  2.0b 4.6  1.3b 0.31  0.1 0.91  0.8 1945
MSH GFP-MEK2 6.8  1.2b 4.6  0.6b 0.32  0.1 0.97  0.9 2009
Time
Melatonin 5 min 4.5  1.1 8.7  3.3 0.33  0.1 1.33  1.6 753
Melatonin 45 min 4.0  2.3 4.2  2.1b 0.30  0.1 0.96  0.8 485
a Average number of runs per melanosome during a 240 s time period. A “run” is any linear movement with a velocity 0.15 m/s that persists
for at least two successive frames (2 s). (For a detailed description of melanosome transport analysis, see Supplemental Experimental
Procedures).
b Significant at p  0.05, as determined by Student’s t test.
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Figure 2. MEK and ERK Activation during Aggregation, and Their Presence on the Melanosomes in a Functional Complex
(A) Melanophore extracts from cells stimulated with 10 nM melatonin were probed with phospho-specific antibodies against ERK and MEK
(PERK and PMEK, respectively). Both MEK and ERK are transiently phosphorylated upon treatment of cells with melatonin (top). There is
also a slight change in the level of MEK and ERK activation during the course of 100 nM MSH treatment (bottom). The time period of melatonin
treatment is indicated at the top.
(B) Melanosomes purified from cells treated with melatonin and probed with antibodies against ERK signaling components. MEK and ERK
are present on the surface of purified melanosomes. In addition, both proteins are transiently phosphorylated upon stimulation of melanophores
with melatonin (PMEK and PERK, respectively). Protein load was normalized such that each lane contained equal levels of MEK or ERK.
(C) Melanosomes from cells treated with 5 M U0126, purified in the presence or absence of U0126, and incubated with 1 mM ATP. ERK is
highly phosphorylated on melanosomes purified away from U0126 (DMSO) when compared to ERK on melanosomes purified in the presence
of U0126. In (A) and (C), sample load was normalized such that each lane contained equal levels of Kinesin-2.
are consistent with previous reports [3, 4]. Transient transport, raises the possibility that one or more ERK
signaling components are localized to the melanosomeactivation of ERK during aggregation is much more strik-
ing than ERK activation kinetics during MSH treatment, surface. Melanosomes were purified through a density
gradient, and the presence of MEK and ERK was deter-in which only a slight increase in phosphorylation is
observed (Figure 2A, bottom panels). mined via Western blot to test this possibility. The results
of this experiment demonstrate that both MEK and ERKMelanophores were treated with latrunculin followed
by melatonin for either 5 or 45 min and melanosome are present on the surface of purified melanosomes
(Figure 2B, bottom panels). Moreover, MEK and ERKmovements were quantified in order to determine
whether the transient activation of ERK during melatonin on purified melanosomes undergo transient activation
upon melatonin treatment (Figure 2B, top panels), dem-treatment correlates to transport in vivo. The level of
melanosome transport correlates with ERK activation onstrating that melanosomal MEK and ERK are sensitive
to the same signaling cascades that affect the cyto-because the number of melanosome runs after 5 min in
melatonin was significantly higher than that of melano- plasmic pool of MEK and ERK.
The observed activation of melanosome-bound ERKsomes in cells treated with melatonin for 45 min (Table
2; Figure S5). This correlation between melanosome mo- during melatonin treatment suggests that MEK and ERK
are in a functional complex on the melanosome surface.tility and ERK activation in vivo suggests that ERK sig-
naling serves to transiently stimulate melanosome trans- Melanosomes were purified from cells treated with 5
M U0126 to inhibit endogenous ERK phosphorylationport at the onset of pigment aggregation.
in order to determine whether melanosomal MEK can
phosphorylate melanosomal ERK. Melanosomes wereFunctional MEK/ERK Complex Is Present
on the Surface of Melanosomes then resuspended in buffer containing ATP with or with-
out U0126. Purified melanosomes incubated with ATPThe ERK signaling’s transient nature during aggregation,
in combination with its specific control of melanosome in the continued presence of U0126 contain no phos-
Table 2. Lysosome Transport in the Presence of U0126
Number of Number of Average Average
Anterograde Retrograde Velocity Run Length
Condition Drug Runsa Runsa (m/s) (m) n
Melatonin DMSO 0.84  0.6 0.88  0.6 0.58  0.2 0.29  0.2 723
Melatonin U0126 0.79  0.6 0.62  0.5 0.59  0.2 0.31  0.2 883
MSH DMSO 1.21  0.6 1.16  0.5 0.59  0.2 0.32  0.3 392
MSH U0126 0.92  0.4 0.84  0.3 0.59  0.2 0.30  0.2 512
a Average number of runs per lysosome during a 20 s time period. A “run” is any linear movement with a velocity 0.34 m/s that persists
for at least two successive frames (0.4 s). (For a detailed description of melanosome transport analysis, see Supplemental Experimental
Procedures).
Significance is at p  0.05, as determined by Student’s t test.
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phorylated ERK (Figure 2C, left lane). In contrast, mela- leagues [14]. In addition, p38/ERK plays a role in the
intracellular transport of adenovirus particles [15]. Com-nosomes incubated with ATP without U0126 do contain
phosphorylated ERK (Figure 2C, right lane), demonstrat- bined with the results presented in this report, these
studies suggest that ERK signaling cascades may playing that melanosome bound MEK can be relieved from
U0126 inhibition and phosphorylate melanosome bound an important role in regulating intracellular transport.
The localization of MEK and ERK to melanosomes isERK. Taken together, these results demonstrate that
signaling-pathway components that regulate melano- supported by recent studies demonstrating the recruit-
ment of signaling complexes to organelles via the usesome transport are localized to the surface of melano-
somes and suggest that they are active in a physiologi- of scaffolding proteins. Members of the JNK pathway
exist in signaling complexes through interaction withcally relevant manner.
scaffolding proteins known as JIPs (JNK-interacting
proteins) [16–19], which may act as both a scaffold forERK Signaling during Aggregation Lies
JNK pathway members and as a link between kinesinDownstream of PKA
and cargo vesicles [20]. In addition, the MAPKKK-Melanosome aggregation by melatonin is known to in-
related kinase MLK (mixed lineage kinase) directly inter-volve signaling through PKA [1, 2], thus raising the ques-
acts with Kinesin-2 and colocalizes with JNK to punctatetion of whether ERK signaling lies in the PKA-mediated
structures along microtubules [21]. There is also evi-pathway or is a separate branch of melatonin-induced
dence of scaffolding of components of the ERK pathwayaggregation. Melanophores were treated with H-89, a
to endosomes/lysosomes. A recent report identified thepotent and specific inhibitor of PKA [12], to test the
novel endosomal/lysosomal protein p14 as a proteinrelationship between ERK signaling and PKA activity.
able to interact with both MEK and the MEK1-scaffoldingDirect inhibition of PKA with H-89 leads to melanosome
protein MP1 [22, 23]. Melanosomes are related to lyso-aggregation. This aggregation, like aggregation trig-
somes, and both organelles share a number of commongered by melatonin treatment, is blocked by U0126 (Fig-
proteins [5], making it an attractive hypothesis that mela-ure S6A). In addition, H-89 treatment results in a transient
nosomal MEK and ERK are complexed via a scaffoldingincrease of ERK phosphorylation in a fashion similar to
protein.melatonin treatment (Figure S6B). Taken together, these
Of great interest is the fact that ERK signaling medi-results demonstrate that ERK signaling lies downstream
ates both anterograde and retrograde melanosomeof PKA activity in the pathway that regulates melano-
transport along microtubules. This provides another ex-some aggregation.
ample of coordination among components of bidirec-In light of a recent report showing the localization of
tional, opposite-polarity transport (for a review of bidi-PKA to the melanosome surface [13], the question arises
rectional transport, see [24]) and suggests that theas to whether ERK signaling components are in a func-
downstream effector of ERK is a novel component oftional complex with PKA. Melanosomes were purified,
transport coordination.incubated with H-89 and ATP, and probed for phosphor-
ylated ERK to test this. In these experiments, we observe
Supplemental Data
no increase in ERK phosphorylation on melanosomes Detailed Experimental Procedures, several figures, and two movies
treated with H-89 (Figure S6C), suggesting that PKA are available at http://www.current-biology.com/cgi/content/full/
15/5/459/DC1/.or one of its downstream effectors required for ERK
activation does not exist in a functional signaling com-
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